Sugi Predict

Sugi Predict / Compounds / SCHEMBL5985

SCHEMBL5985

SCHEMBL5985

Cc1cc(Br)ccc1CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 3/20 0.51
▸ RXRB P28702 3/20 0.51
▸ RXRG P48443 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.47
▸ SRC P12931 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46
▸ PTGS1 P23219 2/20 0.43
▸ AKR1B1 P15121 1/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ PYCR1 P32322 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ AURKA O14965 2/20 0.42
▸ AURKB Q96GD4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30354629 1.00 RXRA (0.51) RXRARXRBRXRGNPSR1SRC
SCHEMBL2351513 0.85 AURKA (0.45) RXRARXRBRXRGSRCPTGS1
SCHEMBL1922484 0.85 MAPT (0.43) RXRARXRBRXRGNPSR1MAPT
SCHEMBL3474780 0.83 SIRT1 (0.42) NPSR1LMNAMAPTPYCR1MEN1
SCHEMBL4817531 0.81 NPSR1 (0.63) RXRARXRBRXRGNPSR1MAPT
SCHEMBL4943725 0.81 ABCB11 (0.43) SRCPTGS1AKR1B1ABCB11LMNA
SCHEMBL4942619 0.81 PTGDR2 (0.44) NPSR1SRCPTGS1AKR1B1ABCB11
SCHEMBL3858358 0.80 NPSR1 (0.52) RXRARXRBRXRGNPSR1MAPT
SCHEMBL9539850 0.80 MEN1 (0.44) LMNAMAPTPYCR1MEN1KMT2A
SCHEMBL13751380 0.80 HPGD (0.45) LMNAMAPTPYCR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed
US-12145924-B2 Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds ELI LILLY AND COMPANY (US) 2024-11-19 — — US disclosed
US-20240343740-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-10-17 — — US disclosed
EP-4359409-A1 DEGRADER COMPOUNDS AND USES THEREOF Calico Life Sciences LLC (US) 2024-05-01 — — EP disclosed
EP-4341255-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS Eli Lilly and Company (US) 2024-03-27 — — EP disclosed
CN-117355517-A Macrocyclic glucagon-like peptide 1 receptor agonists 伊莱利利公司 2024-01-05 — — CN disclosed
EP-3679032-B1 LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS LILLY CO ELI (US) 2023-10-04 — — EP disclosed
CN-111032647-B Lysophosphatidic acid receptor 1 (LPAR 1) inhibitor compounds 伊莱利利公司 2023-05-02 — — CN disclosed
WO-2022271727-A1 DEGRADER COMPOUNDS AND USES THEREOF CALICO LIFE SCIENCES LLC (US) 2022-12-29 — — WO disclosed
WO-2022271727-A1 DEGRADER COMPOUNDS AND USES THEREOF CALICO LIFE SCIENCES LLC (US) 2022-12-29 — — WO disclosed
US-20100113488-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2010-05-06 — — US disclosed
US-20100113488-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2010-05-06 — — US disclosed
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 — — US disclosed
WO-2008079836-A2 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-03 — — WO disclosed
US-20080004301-A1 Benzene Compound Having 2 or More Substituents DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-01-03 — — US disclosed
EP-1806332-A1 BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS Daiichi Sankyo Company, Limited (JP) 2007-07-11 — — EP disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 — — US disclosed
EP-1292593-A2 2-(3,5-DISUBSTITUTED-4-PYRIDYL)-4-(THIENYL, THIAZOLYL OR ARYLPHENYL)-1,3-OXAZOLINE COMPOUNDS Dow AgroSciences LLC (US) 2003-03-19 — — EP disclosed
WO-2001098296-A2 2-(3,5-DISUBSTITUTED-4-PYRIDYL)-4-(THIENYL, THIAZOLYL OR ARYLPHENYL)-1,3-OXAZOLINE COMPOUNDS DOW AGROSCIENCES LLC (US) 2001-12-27 — — WO disclosed
EP-0496548-A1 Carbacyclin analogs PURDUE RESEARCH FOUNDATION (US) 1992-07-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343740-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS GLP1R, GCGR, GIPR RXRA 900/4885RXRB 973/4885RXRG 837/4885
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 RXRA 2664/4885RXRB 2866/4885RXRG 2562/4885
US-12145924-B2 Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds LPAR1, LPAR2, LPAR5 RXRA 1910/4885RXRB 1875/4885RXRG 1963/4885
US-20100113488-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F12, F7, F5 RXRA 650/4885RXRB 689/4885RXRG 1053/4885
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 RXRA 289/4885RXRB 374/4885RXRG 249/4885
US-20080004301-A1 Benzene Compound Having 2 or More Substituents NR1H2, NR1H3, NCOR2 RXRA 5/4885RXRB 4/4885RXRG 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.